This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Zoledronic Acid in the Prevention of Skeletal-related Events in Hormone Refractory and Hormone-sensitive Prostate Cancer Patients With Bone Metastases

This study has been completed.
Società Italiana di Urologia (SIU)
Information provided by (Responsible Party):
Novartis Identifier:
First received: September 7, 2005
Last updated: April 13, 2015
Last verified: April 2015
The present study will give information about the course over time in skeletal-related events (SRE) in prostate cancer patients with bone metastases treated with zoledronic acid 4 mg administered as a 15-minute infusion every 4 weeks for a maximum of 15 infusions. The protocol will enroll patients with recent diagnosis of bone metastases from prostate cancer who are hormone-refractory, hormone-naïve or still hormone-sensitive, that represent the entire population of prostate cancer patients

Condition Intervention Phase
Prostate Cancer Drug: Zoledronic acid Phase 4

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Zoledronic Acid in the Prevention of Skeletal-related Events in Hormone Refractory and Hormone-sensitive Prostate Cancer Patients With Bone Metastases

Resource links provided by NLM:

Further study details as provided by Novartis:

Primary Outcome Measures:
  • occurence of skeletale related events (SREs) over time (time to first SRE,skeletal morbidity rate and proportion of patients experiencing SRE)

Secondary Outcome Measures:
  • Bone pain
  • Use of analgesic medication and ECOG performance status every three months
  • Bone specific alkaline phosphatase, serum N-telopeptide and parathyroid hormone will be evaluated after one month of treatment and then every three months

Study Start Date: September 2003
Estimated Study Completion Date: October 2006

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   No

Inclusion Criteria

  • Patients aged ≥18 years
  • Written informed consent
  • Histologically-proven prostate carcinoma
  • ECOG performance status ≤ 2
  • Life expectancy > 6 months
  • Newly diagnosed (≤ 6 months prior to visit 1) bone metastases evidenced by bone scan or radiograph.
  • Patients on androgen deprivation therapy (medical therapy with LHRH analogues + antiandrogens or surgical castration) or going to start it
  • Patients with partners of childbearing potential should use a barrier method of contraception throughout the study

Exclusion Criteria

  • Patients without a history of metastatic disease to the bone
  • Prior treatment with bisphosphonates
  • SREs prior to visit 2
  • Prior treatment with calcitonin, mithramycin, or gallium nitrate within 2 weeks prior to baseline
  • Corrected (adjusted for serum albumin - see Appendix 5 for the calculation) serum calcium concentration < 8.0 mg/dl (2.00 mmol/l)
  • Serum creatinine concentration > 265 micromol/l (3.0 mg/dl) or a calculated creatinine clearance < 30 ml/minute or serious underlying renal disease or prior renal transplantation
  • History of other malignant neoplasm within previous five years with exception of non-melanomatous skin cancer which has been satisfactorily treated
  • Other known concurrent, severe medical disorder jeopardizing the life of the patient in the immediate future
  • Patients treated with systemic investigational drug(s) and/or device(s) within the past 30 days or topical investigational drugs within the past 7 days
  • Known hypersensitivity to zoledronic acid or other bisphosphonates
  • History of noncompliance to medical regimens and patients who are considered potentially unreliable (for example drug or alchohol abusers) or incapable of giving informed consent as judged by the investigator
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00219219

Bologna, Italy
Sponsors and Collaborators
Società Italiana di Urologia (SIU)
Study Chair: Novartis Novartis
  More Information

Responsible Party: Novartis Identifier: NCT00219219     History of Changes
Other Study ID Numbers: CZOL446EIT04
Study First Received: September 7, 2005
Last Updated: April 13, 2015

Keywords provided by Novartis:
zoledronic acid
prostate cancer

Additional relevant MeSH terms:
Prostatic Neoplasms
Genital Neoplasms, Male
Urogenital Neoplasms
Neoplasms by Site
Genital Diseases, Male
Prostatic Diseases
Zoledronic acid
Hormones, Hormone Substitutes, and Hormone Antagonists
Physiological Effects of Drugs
Bone Density Conservation Agents processed this record on July 19, 2017